Analysts' Top 5 Price Targets of September 30, 2025
Reading Time: 4 minutes
Rapt Therapeutics [US75382E1091] Clear Street confirms the Buy rating and raises the price target from $24 to $41 (54% upside potential) The reason for this optimistic assessment is the FDA approval of the Phase 2b study with the active ingredient RPT904 for the treatment of food allergies. According to analysts, this news represents a significant regulatory hurdle that strengthens confidence in the company's pipeline. The study is set to begin at the end of 2025, with initial results expected in the first half of 2027. Clear Street...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
